Thank you @George1972 very informative at least someone is willing to discuss the issue
One question George ref your does everyone comprehend
How could the EU trial data be a proxy , The trial is placebo based so no data will be forthcoming for at least 16 months from the EU trial
This is an issue i would imagine that will have to be worked through before moving into any trials under the FDA guidance
I suppose an alternative to this George if it does become a major issue would be to push forwards through the FDA with a 12 month trial at the partial hold dosing of 25mg
and once the FDA trial is over on hopefully outstanding results
Then back up an early to market proposal with the FDA asking them to Accept the hopefully by then successful Ph2 trial from the EU along with OUTSTANDING results from the 100mg dosing arm
Thank you George once more for acknowledging and keeping things real and bringing common sense back to the forum
Like i said i have no reservations that this will move forwards, we will find out soon enough what these conditions are
SEE HOW WE GO
- Forums
- ASX - By Stock
- PER
- Ann: US FDA Type C Meeting for ATL1102 in DMD
Ann: US FDA Type C Meeting for ATL1102 in DMD, page-61
-
-
- There are more pages in this discussion • 27 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add PER (ASX) to my watchlist
(20min delay)
|
|||||
Last
8.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $72.12M |
Open | High | Low | Value | Volume |
8.1¢ | 8.1¢ | 7.9¢ | $33.53K | 416.4K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
2 | 92000 | 7.9¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
8.0¢ | 65186 | 3 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
2 | 92000 | 0.079 |
2 | 212658 | 0.078 |
1 | 200000 | 0.077 |
2 | 66500 | 0.076 |
4 | 206988 | 0.075 |
Price($) | Vol. | No. |
---|---|---|
0.080 | 65186 | 3 |
0.082 | 97561 | 1 |
0.083 | 214000 | 1 |
0.084 | 161142 | 2 |
0.085 | 141000 | 2 |
Last trade - 16.10pm 15/07/2024 (20 minute delay) ? |
Featured News
PER (ASX) Chart |
The Watchlist
RCE
RECCE PHARMACEUTICALS LTD
James Graham / Dr Alan Dunton, MD & CEO / Non-Executive Director
James Graham / Dr Alan Dunton
MD & CEO / Non-Executive Director
SPONSORED BY The Market Online